| Mechanism and management of AKT inhibitor-induced hyperglycemia. | |
| | |
MedLine Citation:
|
PMID: 19118049 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Insulin-like growth factor-I receptor and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathways are among the most active areas of drug discovery in cancer research. However, due to their integral roles in insulin signaling, inhibitors targeting these pathways often lead to hyperglycemia and hyperinsulinemia. We investigated the mechanism of hyperglycemia induced by GSK690693, a pan-AKT kinase inhibitor in clinical development, as well as methods to ameliorate these side effects. EXPERIMENTAL DESIGN: The effect of GSK690693 on blood glucose, insulin, and glucagon levels was characterized in mice. We then evaluated the effects of commonly prescribed antidiabetic agents on GSK690693-induced hyperglycemia. The mechanism of blood glucose increase was evaluated using fasting and tracer uptake studies and by measuring liver glycogen levels. Finally, approaches to manage AKT inhibitor-induced hyperglycemia were designed using fasting and low carbohydrate diet. RESULTS: We report that treatment with antidiabetic agents does not significantly affect GSK690693-induced hyperglycemia in rodents. However, administration of GSK690693 in mice significantly reduces liver glycogen (approximately 90%), suggesting that GSK690693 may inhibit glycogen synthesis and/or activate glycogenolysis. Consistent with this observation, fasting before drug administration reduces baseline liver glycogen levels and attenuates hyperglycemia. Further, GSK690693 also inhibits peripheral glucose uptake and introduction of a low-carbohydrate (7%) or 0% carbohydrate diet after GSK690693 administration effectively reduces diet-induced hyperglycemia in mice. CONCLUSIONS: The mechanism of GSK690693-induced hyperglycemia is related to peripheral insulin resistance, increased gluconeogenesis, and/or hepatic glycogenolysis. A combination of fasting and low carbohydrate diet can reduce the magnitude of hyperglycemia induced by an AKT inhibitor. |
| | |
Authors:
|
Ming-Chih Crouthamel; Jason A Kahana; Susan Korenchuk; Shu-Yun Zhang; Gobalakrishnan Sundaresan; Derek J Eberwein; Kathleen K Brown; Rakesh Kumar |
Related Documents
:
|
10579679 - Insulin delivery governed by covalently modified lectin-glycogen gels sensitive to gluc... 13859229 - Metabolism of glycogen in skin and the effect of radiation. 15588649 - Fruit of the jambolan tree (eugenia jambolana lam.) and experimental diabetes. 6234159 - Mercuric chloride intoxication in freshwater prawn. i. effect on carbohydrate metabolism. 12898129 - Hexachlorobenzene impairs glucose metabolism in a rat model of porphyria cutanea tarda:... 7151419 - Metabolism of glucose and glycogen in limulus polyphemus in vivo. 16052859 - Cerebral complications in diabetic ketoacidosis. 17940119 - Genetic variants within the lpin1 gene, encoding lipin, are influencing phenotypes of t... 12926529 - Obesity and reproductive disorders in women. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical cancer research : an official journal of the American Association for Cancer Research Volume: 15 ISSN: 1078-0432 ISO Abbreviation: Clin. Cancer Res. Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-01-01 Completed Date: 2009-05-07 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 9502500 Medline TA: Clin Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 217-25 Citation Subset: IM |
Affiliation:
|
Oncology Biology, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Diet, Carbohydrate-Restricted Fasting Female Hyperglycemia / chemically induced*, prevention & control Liver Glycogen / metabolism Male Mice Mice, SCID Oxadiazoles / pharmacology* Proto-Oncogene Proteins c-akt / antagonists & inhibitors*, metabolism Rats Rats, Sprague-Dawley |
| Chemical | |
Reg. No./Substance:
|
0/GSK690693; 0/Liver Glycogen; 0/Oxadiazoles; EC 2.7.11.1/Proto-Oncogene Proteins c-akt |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: rNAPc2 Inhibits Colorectal Cancer in Mice through Tissue Factor.
Next Document: BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhi...